Selected Grants
SEVERE COUGH A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary f
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2024 - 2029IM027-1015 BMS A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2023 - 2028BMS IM027-068 IPF A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2023 - 2028PHINDER GMS-PH-001
Clinical TrialPrincipal Investigator · Awarded by United Therapeutics Corporation · 2023 - 2028Complement Pathway Activation in Idiopathic Pulmonary Fibrosis and other Progressive Fibrosing Interstitial Lung Diseases (K23)
ResearchPrincipal Investigator · Awarded by National Heart, Lung, and Blood Institute · 2023 - 2028Clinetic Retrospective Registry Study (PI Initiated)
ResearchPrincipal Investigator · Awarded by Clinetic, Inc · 2024 - 2027Enhancing Capacity of the PCORnet® Common Data Model to Support PCORI Priorities in Patient-Centered CER
ResearchPrincipal Investigator · Awarded by Vanderbilt University Medical Center · 2024 - 2026PPF Retrospective Analysis (PPF)
ResearchPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2023 - 2025US Patient Engagement
ResearchPrincipal Investigator · Awarded by GB002, Inc. · 2025 - 2025Comparative effectiveness of VNS versus continued pharmacologic treatment of Lennox-Gastaut Syndrome
ResearchPrincipal Investigator · Awarded by Ann & Robert H. Lurie Children's Hospital of Chicago · 2024 - 2025CHARACTERIZING THE ILD CARE CONTINUUM USING REAL-WORLD EVIDENCE
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2021 - 2024External Relationships
- United Therapeutics Corp.
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.